Company: BLCO
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001860742-25-000018
Chunk: 118

Company: Bausch & Lomb Corp
Filing Date: 2025-07-30
Form: 10-Q
Item: Item 2
Chunk 118
---
) income(11)26 (37)(94)32 (126)Interest income3 3 — 6 6 — Interest expense(128)(102)(26)(222)(201)(21)Loss on extinguishment of debt(9)— (9)(9)— (9)Foreign exchange and other(2)(3)1 (8)(3)(5)Loss before provision for income taxes(147)(76)(71)(327)(166)(161)Benefit from (provision for income taxes)89 (72)161 58 (145)203 Net loss(58)(148)90 (269)(311)42 Net income attributable to noncontrolling interest(4)(3)(1)(5)(7)2 Net loss attributable to Bausch + Lomb Corporation$(62)$(151)$89 $(274)$(318)$44 

38

Three Months Ended June 30, 2025 Compared to the Three Months Ended June 30, 2024Revenues Our revenues are primarily generated from product sales in the therapeutic areas of eye health that consist of: (i) branded prescription eye-medications and pharmaceuticals, (ii) generic and branded generic prescription eye medications and pharmaceuticals, (iii) OTC vitamin and supplement products and (iv) medical devices (contact lenses, IOLs and ophthalmic surgical equipment). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 17, “SEGMENT INFORMATION” to our unaudited interim Condensed Consolidated Financial Statements for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.Our revenues were $1,278 million and $1,216 million for the three months ended June 30, 2025 and 2024, respectively, an increase of $62 million, or 5%. The increase was attributable to: (i) increased volumes of $64 million within our Vision Care and Pharmaceuticals segments, (ii) the favorable impact of foreign currencies of $21 million and (iii) incremental sales attributable to acquisitions of $6 million, within our Surgical segment. The increases in revenue were partially offset by: (i) decreased net realized pricing of $27 million, driven by our Pharmaceuticals segment and